PORTLAND, Ore., Jan. 31, 2026 — Trace Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for LGW16-03, the company’s first nerve-specific fluorescent imaging agent. The regulatory clearance allows Trace to initiate first-in-human clinical studies evaluating the safety and intraoperative performance of the agent in surgical settings, marking a pivotal step toward improving nerve visualization during complex procedures.
Science Significance
LGW16-03, also known as NerveTrace Dx, is a small-molecule imaging agent designed to selectively bind peripheral nerves and emit a near-infrared fluorescent signal. This enables surgeons to visualize critical nerve structures in real time, even when nerves are buried beneath tissue layers or are sub-millimeter in size. Accidental nerve injury remains a persistent and under-addressed challenge across procedures such as orthopedic, urologic, colorectal, and head-and-neck surgeries, often resulting in chronic pain, incontinence, numbness, or permanent loss of function. Scientifically, LGW16-03 represents a major advance in fluorescence-guided surgery, transforming nerve identification from an anatomical estimation into a data-driven visual process that can enhance surgical precision and safety.
Regulatory Significance
The FDA’s IND clearance confirms that Trace Biosciences has met rigorous preclinical safety, toxicology, and manufacturing requirements necessary to proceed into human studies under Good Clinical Practice (GCP) standards. Imaging agents administered systemically during surgery face heightened regulatory scrutiny due to their intraoperative use and interaction with surgical devices. Approval of the IND demonstrates regulatory confidence in the quality, reproducibility, and safety profile of LGW16-03, and establishes a formal regulatory pathway for future clinical expansion across multiple surgical indications. From a cGxP perspective, this milestone highlights the increasing regulatory maturity of drug-enabled surgical technologies.
Business Significance
Advertisement
For Trace Biosciences, IND clearance represents a transformational business milestone, transitioning the company from preclinical innovation into clinical-stage execution. The ability to initiate Phase I studies strengthens the commercial and strategic value of Trace’s nerve-targeted imaging platform, which has applications beyond a single procedure type. As hospitals seek technologies that reduce complications and associated costs, real-time nerve visualization tools could become integral to modern surgical workflows. Successful early clinical data may unlock partnerships with device manufacturers, healthcare systems, or strategic investors, positioning Trace at the intersection of biotechnology and MedTech innovation.
Patients’ Significance
For patients, the potential impact of LGW16-03 is substantial. Nerve injuries during surgery can lead to lifelong physical, emotional, and economic consequences, often requiring ongoing medical care. By enabling surgeons to see nerves clearly and avoid inadvertent damage, LGW16-03 could significantly reduce postoperative complications and improve long-term quality of life. Enhanced nerve preservation may also translate into shorter recovery times, fewer follow-up interventions, and improved functional outcomes, aligning surgical innovation with patient-centered care.
Policy Significance
The advancement of LGW16-03 aligns with broader healthcare policy priorities focused on patient safety, surgical quality improvement, and innovation in regulated medical technologies. Regulatory support for imaging agents that integrate seamlessly with existing surgical systems reflects a growing recognition of technology-enabled precision surgery. As healthcare systems aim to reduce complication-related costs and improve outcomes, nerve-visualization technologies may influence future clinical guidelines, reimbursement discussions, and adoption policies at institutional and national levels.
With FDA IND clearance secured, Trace Biosciences is poised to begin Phase I clinical evaluation of LGW16-03, initially in orthopedic surgery, with plans to expand into additional high-risk surgical areas. The milestone underscores how rigorous GxP-aligned development, combined with scientific innovation, can bring forward tools that fundamentally change surgical practice. As LGW16-03 progresses through clinical development, it represents a compelling example of how MedTech innovation powered by regulated drug development can advance surgical safety and patient outcomes.
Source: Trace Biosciences press release
